JP2012518164A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012518164A5 JP2012518164A5 JP2011549604A JP2011549604A JP2012518164A5 JP 2012518164 A5 JP2012518164 A5 JP 2012518164A5 JP 2011549604 A JP2011549604 A JP 2011549604A JP 2011549604 A JP2011549604 A JP 2011549604A JP 2012518164 A5 JP2012518164 A5 JP 2012518164A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- subject
- platinum
- rbm3
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 22
- 101001076867 Homo sapiens RNA-binding protein 3 Proteins 0.000 claims 17
- 102100025902 RNA-binding protein 3 Human genes 0.000 claims 17
- 229910052697 platinum Inorganic materials 0.000 claims 11
- 239000003446 ligand Substances 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 230000009834 selective interaction Effects 0.000 claims 6
- 108020004999 messenger RNA Proteins 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical group N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims 1
- 229950005566 picoplatin Drugs 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229960005399 satraplatin Drugs 0.000 claims 1
- 190014017285 satraplatin Chemical compound 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SE2009/000091 WO2009102261A1 (en) | 2008-02-15 | 2009-02-16 | Rbm3 as a marker for breast cancer prognosis |
| SEPCT/SE2009/000091 | 2009-02-16 | ||
| US16996309P | 2009-04-16 | 2009-04-16 | |
| EP09158084.5 | 2009-04-16 | ||
| US61/169,963 | 2009-04-16 | ||
| EP09158084A EP2241889A1 (en) | 2009-04-16 | 2009-04-16 | RBM3 protein in colorectal cancer prognostics |
| US23376909P | 2009-08-13 | 2009-08-13 | |
| US61/233,769 | 2009-08-13 | ||
| EP09167847.4 | 2009-08-13 | ||
| EP09167847A EP2293070A1 (en) | 2009-08-13 | 2009-08-13 | Means and methods for ovarian cancer prognosis |
| EPPCT/EP2009/067419 | 2009-12-17 | ||
| PCT/EP2009/067419 WO2010091763A1 (en) | 2009-02-16 | 2009-12-17 | Rbm3 as a marker for malignant melanoma prognosis |
| PCT/EP2010/051941 WO2010092190A2 (en) | 2009-02-16 | 2010-02-16 | Prediction of response to platinum-based therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012518164A JP2012518164A (ja) | 2012-08-09 |
| JP2012518164A5 true JP2012518164A5 (enExample) | 2013-04-04 |
| JP5767116B2 JP5767116B2 (ja) | 2015-08-19 |
Family
ID=41718882
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549601A Expired - Fee Related JP5611986B2 (ja) | 2009-02-16 | 2010-02-16 | 結腸直腸癌の予後診断におけるｒｂｍ３タンパク質 |
| JP2011549603A Expired - Fee Related JP5669757B2 (ja) | 2009-02-16 | 2010-02-16 | 精巣癌診断および予後診断におけるｒｂｍ３タンパク質 |
| JP2011549604A Expired - Fee Related JP5767116B2 (ja) | 2009-02-16 | 2010-02-16 | 白金に基づく治療に対する応答の予測 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549601A Expired - Fee Related JP5611986B2 (ja) | 2009-02-16 | 2010-02-16 | 結腸直腸癌の予後診断におけるｒｂｍ３タンパク質 |
| JP2011549603A Expired - Fee Related JP5669757B2 (ja) | 2009-02-16 | 2010-02-16 | 精巣癌診断および予後診断におけるｒｂｍ３タンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8632984B2 (enExample) |
| EP (4) | EP2396657B1 (enExample) |
| JP (3) | JP5611986B2 (enExample) |
| CN (1) | CN102334032B (enExample) |
| AU (4) | AU2009339802B2 (enExample) |
| CA (3) | CA2749349A1 (enExample) |
| DK (2) | DK2396660T3 (enExample) |
| WO (5) | WO2010091763A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2396657B1 (en) * | 2009-02-16 | 2013-11-13 | Atlas Antibodies AB | Rbm3 as a marker for malignant melanoma prognosis |
| EP2524928A1 (en) | 2011-05-18 | 2012-11-21 | Atlas Antibodies AB | RBM3 in bladder cancer |
| EP2630498A4 (en) * | 2010-10-22 | 2014-10-01 | Vermillion Inc | PROGNOSTIC BIOMARKERS IN PATIENTS WITH OVARIAN CANCER |
| US20120288480A1 (en) * | 2011-02-22 | 2012-11-15 | Taipei Medical University | Cell population comprising orbital fat-derived stem cells (ofscs) and their isolation and applications |
| EP2573566A1 (en) | 2011-09-20 | 2013-03-27 | Atlas Antibodies AB | RBM3 in prostate cancer prognostics |
| CN102590185B (zh) * | 2012-01-11 | 2013-12-25 | 东南大学 | 以适体为识别单元的胶体晶体凝胶非标记可视化检测方法 |
| WO2016004387A1 (en) * | 2014-07-02 | 2016-01-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Gene expression signature for cancer prognosis |
| EP3023791A1 (en) * | 2014-11-21 | 2016-05-25 | Atlas Antibodies AB | Predicting the responsiveness to gemcitabine treatment |
| CN106611094B (zh) * | 2015-10-15 | 2021-08-06 | 北京寻因生物科技有限公司 | 基于肠道微生物菌群预测及干预化疗药物毒副反应的系统 |
| CN113373151B (zh) * | 2021-06-30 | 2022-05-03 | 华中科技大学同济医学院附属协和医院 | 环状RNAhsa_circ_0008399的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| GB9917027D0 (en) | 1999-07-20 | 1999-09-22 | Affibody Technology Sweeden Ab | In vitro selection and optional identification of polypeptides using solid support carriers |
| US6602670B2 (en) * | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
| US6686155B2 (en) * | 2001-06-14 | 2004-02-03 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression |
| WO2006071896A2 (en) * | 2004-12-23 | 2006-07-06 | The Hong Kong University Of Science And Technology | Epitope-based sars vaccine |
| EP1934867A2 (en) | 2005-08-31 | 2008-06-25 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| US20090007281A1 (en) | 2006-01-13 | 2009-01-01 | Battelle Memorial Institute | Animal Model for Assessing Copd-Related Diseases |
| EP1862803A1 (en) * | 2006-06-02 | 2007-12-05 | Atlas Antibodies AB | Use of protein SATB2 as a marker for colorectal cancer |
| EP2090890A1 (en) * | 2008-02-15 | 2009-08-19 | Atlas Antibodies AB | RBM3 as a marker for breast cancer prognosis |
| US7902166B2 (en) | 2008-04-03 | 2011-03-08 | The Board Of Regents Of The University Of Oklahoma | Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same |
| EP2396657B1 (en) * | 2009-02-16 | 2013-11-13 | Atlas Antibodies AB | Rbm3 as a marker for malignant melanoma prognosis |
| EP2524928A1 (en) * | 2011-05-18 | 2012-11-21 | Atlas Antibodies AB | RBM3 in bladder cancer |
-
2009
- 2009-12-17 EP EP09803750.0A patent/EP2396657B1/en not_active Not-in-force
- 2009-12-17 US US13/201,742 patent/US8632984B2/en not_active Expired - Fee Related
- 2009-12-17 WO PCT/EP2009/067419 patent/WO2010091763A1/en not_active Ceased
- 2009-12-17 AU AU2009339802A patent/AU2009339802B2/en not_active Ceased
-
2010
- 2010-02-16 US US13/201,740 patent/US20120058202A1/en not_active Abandoned
- 2010-02-16 AU AU2010212764A patent/AU2010212764B2/en not_active Ceased
- 2010-02-16 JP JP2011549601A patent/JP5611986B2/ja not_active Expired - Fee Related
- 2010-02-16 WO PCT/EP2010/051920 patent/WO2010092184A1/en not_active Ceased
- 2010-02-16 EP EP10704928.0A patent/EP2396660B1/en not_active Not-in-force
- 2010-02-16 JP JP2011549603A patent/JP5669757B2/ja not_active Expired - Fee Related
- 2010-02-16 US US13/201,689 patent/US8747910B2/en not_active Expired - Fee Related
- 2010-02-16 EP EP10704927A patent/EP2396659B1/en not_active Not-in-force
- 2010-02-16 EP EP10705141A patent/EP2396346B1/en not_active Not-in-force
- 2010-02-16 AU AU2010212772A patent/AU2010212772B2/en not_active Ceased
- 2010-02-16 DK DK10704928.0T patent/DK2396660T3/da active
- 2010-02-16 AU AU2010212769A patent/AU2010212769C1/en not_active Ceased
- 2010-02-16 CA CA2749349A patent/CA2749349A1/en not_active Abandoned
- 2010-02-16 CA CA2749392A patent/CA2749392A1/en not_active Abandoned
- 2010-02-16 WO PCT/EP2010/051917 patent/WO2010092182A1/en not_active Ceased
- 2010-02-16 CN CN201080007960.0A patent/CN102334032B/zh not_active Expired - Fee Related
- 2010-02-16 WO PCT/EP2010/051935 patent/WO2010092187A1/en not_active Ceased
- 2010-02-16 JP JP2011549604A patent/JP5767116B2/ja not_active Expired - Fee Related
- 2010-02-16 CA CA2749350A patent/CA2749350A1/en not_active Abandoned
- 2010-02-16 WO PCT/EP2010/051941 patent/WO2010092190A2/en not_active Ceased
- 2010-02-16 DK DK10704927.2T patent/DK2396659T3/da active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012518164A5 (enExample) | ||
| Nienhüser et al. | Angiogenesis and anti-angiogenic therapy in gastric cancer | |
| JP2012518163A5 (enExample) | ||
| JP2014521308A5 (enExample) | ||
| JP2012518162A5 (enExample) | ||
| CN110462065A (zh) | 检测肿瘤复发的方法 | |
| NZ591137A (en) | Methods and systems for predicting response of cells to a therapeutic agent | |
| ES3023842T3 (en) | Methods for prostate cancer detection and treatment | |
| EP3236262A3 (en) | Surrogate functional diagnostics test for cancer | |
| JP2015523569A5 (enExample) | ||
| JP7724265B2 (ja) | 遺伝子発現アッセイを使った予測ペプチド受容体放射性核種療法 | |
| JP2019534321A5 (enExample) | ||
| Yin et al. | Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients | |
| Zhang et al. | Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial | |
| Feldman | Update in germ cell tumours | |
| Suematsu et al. | Clinical significance of EREG gene expression in gastric cancer tissue after curative surgery | |
| Xu et al. | ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer | |
| Zhang et al. | Low expression of circular RNA hsa_circ_0078607 predicts poor prognosis in high-grade serous ovarian cancer | |
| Luo et al. | Sensitive small extracellular vesicles associated circRNAs analysis combined with machine learning for precision identification of gastric cancer | |
| JP2014517282A5 (enExample) | ||
| Choi et al. | Regional bias of intratumoral genetic heterogeneity of nucleotide repeats in colon cancers with microsatellite instability | |
| JP2016508219A5 (enExample) | ||
| Liu et al. | Self-circulating electrochemiluminescence chip for sensitive detection of circulating tumour nucleic acids in blood | |
| WO2022020520A1 (en) | A deep learning framework to identify pathogenic non-coding somatic mutations from personal cancer genomes | |
| WO2012003493A3 (en) | Protein kinase ck2 gene mutations, amplifications and polymorphisms in human cancers and methods of use |